Condition
MTAP Deletion
Total Trials
5
Recruiting
3
Active
4
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
P 1 (3)
P 2 (1)
Trial Status
Recruiting3
Active Not Recruiting1
Not Yet Recruiting1
Clinical Trials (5)
Showing 5 of 5 trials
NCT06630416Phase 2Recruiting
Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors
NCT07593573Active Not Recruiting
the Exploration of MTAP Deletion in Osteosarcoma by Immunohistochemistry
NCT06922591Phase 1Recruiting
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
NCT07567859Phase 1Not Yet RecruitingPrimary
A Study of HS-10587 in Patients With Advanced Solid Tumors
NCT06973863Phase 1Recruiting
A Study of PEP08 in Patients With MTAP-Del Advanced or Metastatic Solid Tumors
Showing all 5 trials